Department of Urology, Western Health and Social Care Trust, Derry, Northern Ireland.
J Urol. 2024 Dec;212(6):821-831. doi: 10.1097/JU.0000000000004226. Epub 2024 Aug 27.
Enhanced histological detection of clinically significant prostate cancer is the goal of the prebiopsy imaging pathway. Risk stratification at a prebiopsy meeting can facilitate optimization of lesion targeting. We aimed to evaluate the feasibility of cognitive registration, freehand transperineal prostate biopsy in a biopsy-naïve population following biparametric MRI for the detection of clinically significant disease (International Society of Urological Pathology Grade Group ≥2).
A consecutive series of biopsy-naïve men, prospectively recorded between July 2018 and March 2023, were risk-stratified at our prebiopsy meeting following biparametric MRI to undergo either target-only biopsy or target with systematic biopsy. Biopsies were routinely performed under local anesthesia and without antibiotic prophylaxis in the outpatient setting. Overall prostate cancer and clinically significant prostate cancer detection were primary outcomes.
Of 1251 biopsies, prostate cancer was detected in 84% and clinically significant disease in 70.6%. Prostate cancer and clinically significant disease were detected in 86.2% and 76.5% of target-only biopsies, respectively, and in 78.7% and 56.3% of target with systematic biopsies. Postbiopsy complication rate was 0.7%.
Prebiopsy biparametric MRI with risk stratification at a prebiopsy meeting in the setting of cognitive targeting and freehand transperineal prostate biopsy yielded a high detection of prostate cancer that is comparable to other studies. These data support the use of cognitive registration, freehand transperineal prostate biopsy as safe, feasible, and cost-effective.
提高临床显著前列腺癌的组织学检测水平是活检前影像学路径的目标。在活检前会议上进行风险分层可以促进病变靶向的优化。我们旨在评估在双参数 MRI 检测临床显著疾病(国际泌尿病理学会分级组≥2)后,对活检初治人群进行认知配准、徒手经会阴前列腺活检的可行性。
前瞻性记录了 2018 年 7 月至 2023 年 3 月期间连续的活检初治男性患者,在我们的活检前会议上进行风险分层,这些患者接受靶向活检或靶向与系统活检。活检在局麻下、门诊环境下、无抗生素预防的情况下常规进行。总体前列腺癌和临床显著前列腺癌的检出是主要结果。
在 1251 次活检中,84%的患者检出前列腺癌,70.6%的患者检出临床显著疾病。靶向活检分别检出 86.2%和 76.5%的前列腺癌和临床显著疾病,靶向加系统活检分别检出 78.7%和 56.3%的前列腺癌和临床显著疾病。活检后并发症发生率为 0.7%。
在认知靶向和徒手经会阴前列腺活检的背景下,进行活检前双参数 MRI 检查并在活检前会议上进行风险分层,可提高前列腺癌的检出率,与其他研究相当。这些数据支持使用认知配准、徒手经会阴前列腺活检,因为其安全、可行且具有成本效益。